<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052610</url>
  </required_header>
  <id_info>
    <org_study_id>502-12-760, 503-2056-1</org_study_id>
    <nct_id>NCT01052610</nct_id>
  </id_info>
  <brief_title>Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites</brief_title>
  <official_title>Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to asses the efficacy and safety of sublingual annual
      immunotherapy in children with bronchial asthma and/or allergic rhinitis allergic to house
      dust mites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergen immunotherapy is currently the only one method of cause treatment of the
      IgE-dependent allergic diseases. Sublingual immunotherapy (SLIT) is the method which allows
      to give allergens via alternative oral route in patients home. Due to possibility of avoiding
      injection this therapy offers better relationship with pediatric patient. However efficacy
      and safety of sublingual immunotherapy are still important issues, especially in asthmatic
      children. The purpose of the trial is to asses the efficacy and safety of sublingual annual
      immunotherapy in children with bronchial asthma and/or allergic rhinitis allergic to house
      dust mites.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical symptoms of asthma and allergic rhinitis and use of rescue medication</measure>
    <time_frame>Visit No 2 (before SLIT),VISIT No 4(after 1 year of SLIT), Visit No 6(after 3 years of SLIT)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of percent of regulatory lymphocytes in peripheral blood</measure>
    <time_frame>Visit No 2 (before SLIT),VISIT No 4(after 1 year of SLIT), Visit No 6(after 3 years of SLIT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of inflammatory markers in exhaled breath condensate and FeNO</measure>
    <time_frame>Visit No 2 (before SLIT),VISIT No 4(after 1 year of SLIT), Visit No 6(after 3 years of SLIT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-specific bronchial hyperreactivity with methacholine (PC20M), specific conjunctival provocation test</measure>
    <time_frame>Visit No 2 (before SLIT),VISIT No 4(after 1 year of SLIT), Visit No 6(after 3 years of SLIT)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bronchial Asthma</condition>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sublingual house dust mites allergen extract</intervention_name>
    <description>Staloral 300 IR, Stallergenes, France</description>
    <arm_group_label>Active group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo in sublingual applicator</intervention_name>
    <description>placebo for Staloral 300 IR, Stallergenes, France</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with bronchial asthma and/or allergic rhinitis allergic to house dust mites
             first diagnosed at least 2 years before the study

        Exclusion Criteria:

          -  active respiratory tract infection requiring antibiotic treatment within 4 weeks
             before the study

          -  hospitalisation due to asthma exacerbation during the 3 months before the first visit

          -  known contraindications of SIT according to the EAACI

          -  previous allergen immunotherapy

          -  use of systemic corticosteroids

          -  other clinically significant pulmonary, hematologic, hepatic, gastrointestinal, renal,
             endocrine, neurologic, cardiovascular, and/or mental diseases or malignancy that
             either put the patient at risk when participating in the study or could influence the
             results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iwona Stelmach, MD, PhD, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics and Allergy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iwona Stelmach, MD, PhD, Prof</last_name>
    <phone>+48426895972</phone>
    <email>alergol@kopernik.lodz.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pediatrics and Allergy</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Bobrowska-Korzeniowska, MD, PhD</last_name>
      <phone>426895972</phone>
      <email>alergol@kopernik.lodz.pl</email>
    </contact>
    <investigator>
      <last_name>Monika Bobrowska-Korzeniowska, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnieszka Brzozowska, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Universtity of Lodz</investigator_affiliation>
    <investigator_full_name>Iwona Stelmach</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>SLIT</keyword>
  <keyword>bronchial asthma</keyword>
  <keyword>allergic rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

